每日步数模式与美国成人死亡风险的关联
该队列研究基于美国国家健康与营养调查2005-2006中3101名20岁及以上佩戴加速度计1周的参与者,按每周达到8000步以上的天数分为0天、1–2天和3–7天组,随访至2019年12月31日。10年随访期间,全因死亡439例(14.2%)、心血管死亡148例(5.3%)。与每周0天达到8000步以上者相比,1–2天组全因死亡调整风险差为-14.9%(95%CI -18.8%至-10.9%),3–7天组为-16.5%(95%CI -20.4%至-12.5%);全因和心血管死亡风险的剂量-反应关系呈曲线形,保护性关联在每周3天时趋于平台,每日步数阈值在6000至10000之间调整结果相似。该研究提示,每周仅几天步行即可获得可观健康获益。
要点
- 每周8000步以上1–2天者全因死亡风险差为-14.9%(95%CI -18.8%至-10.9%),3–7天者为-16.5%(95%CI -20.4%至-12.5%)。
- 全因和心血管死亡风险的剂量-反应关联呈曲线形,保护性关联在每周3天时趋于平台。
- 每日步数阈值在6000至10000之间调整,结果相似。
- 10年随访期间全因死亡439例(14.2%)、心血管死亡148例(5.3%)。
- 该研究提示个体每周仅步行几天即可获得实质性健康获益。
适用人群与场景
- 美国国家健康与营养调查2005-2006中20岁及以上、佩戴加速度计1周的代表性样本,共3101人。
研究设计与关键结果
- 研究类型为队列研究;样本量3101人(平均[SD]年龄50.5[18.4]岁;女性1583人[51.0%],男性1518人[49.0%];黑人666人[21.5%],西班牙裔734人[23.7%],白人1579人[50.9%],其他种族和族裔122人[3.9%])。
- 632人(20.4%)每周没有任何一天达到8000步以上,532人(17.2%)每周1–2天达到8000步以上,1937人(62.5%)每周3–7天达到8000步以上。
- 10年随访期间全因死亡439例(14.2%)、心血管死亡148例(5.3%)。
- 与每周0天达到8000步以上者相比,每周1–2天者全因死亡调整风险差为-14.9%(95%CI -18.8%至-10.9%),每周3–7天者为-16.5%(95%CI -20.4%至-12.5%)。
- 全因和心血管死亡风险的剂量-反应关联呈曲线形,保护性关联在每周3天时趋于平台。
- 每日步数阈值在6000至10000之间调整,结果相似。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 该研究提示,个体每周仅步行几天即可获得实质性健康获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Previous studies have shown that individuals who regularly walk, particularly 8000 daily steps or more, experience lower mortality. However, little is known about the health benefits of walking intensively only a few days a week.
OBJECTIVE: To evaluate the dose-response association between the number of days an individual takes 8000 steps or more and mortality among US adults.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study evaluated a representative sample of participants aged 20 years or older in the National Health and Nutrition Examination Surveys 2005-2006 who wore an accelerometer for 1 week and their mortality data through December 31, 2019. Data were analyzed from April 1, 2022, to January 31, 2023.
EXPOSURES: Participants were grouped by the number of days per week they took 8000 steps or more (0 days, 1-2 days, and 3-7 days).
MAIN OUTCOMES AND MEASURES: Multivariable ordinary least squares regression models were used to estimate adjusted risk differences (aRDs) for all-cause and cardiovascular mortality during the 10-year follow-up, adjusting for potential confounders (eg, age, sex, race and ethnicity, insurance status, marital status, smoking, comorbidities, and average daily step counts).
RESULTS: Among 3101 participants (mean [SD] age, 50.5 [18.4] years; 1583 [51.0%] women and 1518 [49.0%] men; 666 [21.5%] Black, 734 [23.7%] Hispanic, 1579 [50.9%] White, and 122 [3.9%] other race and ethnicity), 632 (20.4%) did not take 8000 steps or more any day of the week, 532 (17.2%) took 8000 steps or more 1 to 2 days per week, and 1937 (62.5%) took 8000 steps or more 3 to 7 days per week. Over the 10-year follow-up, all-cause and cardiovascular deaths occurred in 439 (14.2%) and 148 (5.3%) participants, respectively. Compared with participants who walked 8000 steps or more 0 days per week, all-cause mortality risk was lower among those who took 8000 steps or more 1 to 2 days per week (aRD, -14.9%; 95% CI -18.8% to -10.9%) and 3 to 7 days per week (aRD, -16.5%; 95% CI, -20.4% to -12.5%). The dose-response association for both all-cause and cardiovascular mortality risk was curvilinear; the protective association plateaued at 3 days per week. Different thresholds for the number of daily steps between 6000 and 10 000 yielded similar results.
CONCLUSIONS AND RELEVANCE: In this cohort study of US adults, the number of days per week taking 8000 steps or more was associated with a lower risk of all-cause and cardiovascular mortality in a curvilinear fashion. These findings suggest that individuals may receive substantial health benefits by walking just a couple days a week.
参考来源
- Inoue K, Tsugawa Y, Mayeda ER, et al. Association of Daily Step Patterns With Mortality in US Adults. JAMA Netw Open. 2023. PMID: 36976556. doi:10.1001/jamanetworkopen.2023.5174
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。